SGLT2 Inhibitor for Severe Tricuspid Regurgitation - Trial NCT05686616
Access comprehensive clinical trial information for NCT05686616 through Pure Global AI's free database. This phase not specified trial is sponsored by Samsung Medical Center and is currently Recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 72 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Samsung Medical Center
Timeline & Enrollment
N/A
Apr 13, 2022
Mar 03, 2025
Primary Outcome
Difference of RVESVi by CMR from baseline to 12 months follow-up (∆RVESVi)
Summary
The purpose of this study to identify the efficacy of sodium glucose cotransporter 2
 inhibitors add-on treatment on right ventricular remodeling and the amount of severe
 tricuspid regurgitation (TR) in patients with isolated severe TR.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05686616
Non-Device Trial